EL
ALNY icon

Essex LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Essex LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-546
Closed -$217K – 177
2025
Q4 		$217K Sell
546
-1
-0.2% -$443 0.04% 170
2025
Q3 		$249K Sell
547
-241
-31% -$98.1K 0.05% 154
2025
Q2 		$257K Hold
788
– – 0.05% 152
2025
Q1 		$213K Buy
+788
New +$203K 0.05% 159
2024
Q4 		– Sell
-788
Closed -$217K – 171
2024
Q3 		$217K Buy
+788
New +$205K 0.04% 160

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Essex LLC's ALNY Position: Q1 2026 in Review

Essex LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 546 shares — an estimated $217K sold.

Essex LLC first reported a position in ALNY in Q3 2024 and held it in 5 quarters. The position peaked at $257K in Q2 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Essex LLC reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Essex LLC sold 546 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $217K.
  • Essex LLC first reported a position in Alnylam Pharmaceuticals in Q3 2024 and held it in 5 quarters.
  • Essex LLC's Alnylam Pharmaceuticals position peaked at $257K in Q2 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Essex LLC's 13F filing for Q1 2026, filed 24 Apr 2026.